Texas House Bill HB1700

Texas 2009 - 81st Regular

Caption

Relating to the use of funds awarded by the Cancer Prevention and Research Institute of Texas.

Impact

If enacted, HB1700 would significantly impact state laws regarding funding and governance of cancer research. By explicitly disallowing the use of state funds for specific types of stem cell research, the bill reinforces the state's stance on the ethical implications of embryonic research. It sets a precedent on the scope of what types of research can receive public backing, potentially limiting future advancements that rely on embryonic stem cell investigations while promoting alternatives that do not carry the same ethical controversies.

Summary

House Bill 1700 focuses on regulating the use of funds awarded by the Cancer Prevention and Research Institute of Texas. The bill specifically amends Section 102.203 of the Health and Safety Code, introducing a prohibition against using awarded funds for embryonic or fetal stem cell research. However, the bill does allow for the use of funds for research involving adult stem cells or stem cells obtained from umbilical cords, which signifies a clear boundary in the types of stem cell research that can be funded with state resources. This legislative measure underscores the ongoing ethical debates surrounding stem cell research modalities.

Contention

The bill may generate points of contention within the legislative process, particularly related to the balance between ethical considerations in research funding and the potential limitations it imposes on scientific advancement. Advocates of HB1700 may argue that it aligns with ethical standards upheld by many constituents in Texas, while opponents may contend that it restricts significant avenues of cancer research that could have substantial benefits. The debate will likely hinge on the benefits of embryonic stem cell research in treating various health conditions against the interpreted moral implications it presents.